Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Nov 7, 2006

SRI International Recipient of $56.9M from the NIAID

  • SRI International has been awarded a $56.9-million contract from the NIAID to provide preclinical services for the development of drugs and antibodies for anti-infective therapeutics.

    SRI will support the development of treatments for avian flu, SARS, West Nile virus, hepatitis, and biodefense pathogens and toxins for five years. The company will perform medicinal chemistry, custom drug synthesis, formulation, analytical chemistry, clinical manufacturing, microbiology and virology screening, pharmacokinetics, safety testing, and preparation of IND applications to the FDA.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »